Over
a third of participants with an eligible CD4 cell count in a cohort of HIV
serodiscordant couples in Nairobi, Kenya had not started ART within a year in
spite of regular CD4 testing, referrals to local treatment programmes,
counselling on the importance of ART and free access to drugs.
Brandon L.
Guthrie and colleagues report their findings from a two-year prospective study in the
advance online edition of the Journal of
Acquired Immune Deficiency Syndromes.
While
there were no direct costs associated with treatment, indirect costs including
transportation delayed ART start. The lower the socioeconomic status among participants,
the greater the delay in starting ART. After adjusting for CD4 cell count those
paying higher rents started ART at half the rate of homeowners and those paying
lower rents did so at a third of the rate of homeowners.
The
benefits of antiretroviral treatment are well known. In sub-Saharan Africa close to 50% of those in need of ART are not
getting it. Approximately half of all
couples affected by HIV are in discordant relationships.
Timely start of ART in
such couples benefits both the infected partner as well as reducing the risk of
transmission to the uninfected partner. A couples-centred approach with the
uninfected partner involved in the decision-making process of starting ART and providing
support once treatment starts can be an effective strategy to ultimately
improve treatment outcomes.
Attention
has been focused on system-level barriers to ART, notably on making
antiretroviral drugs more affordable. Little attention has been directed to
what happens at the individual level when drugs are freely available.
The
authors cite studies in South Africa that have shown that within a year of
receiving an HIV diagnosis and eligible CD4 cell count only 39% started ART.
Poor
retention in pre-ART programmes is one of the primary obstacles to improving
ART coverage.
The
authors chose to follow a cohort of HIV discordant couples where both partners
were aware of each other’s HIV status to look at the time to starting ART and
those factors that delayed the start and so identify potential interventions.
From
September 2007 to December 2009 439 discordant couples were recruited from
voluntary counselling and testing centres in Nairobi, Kenya.
Eligible couples reported sex three or more times in the three months before
screening and planned to stay together for the length of the study. They agreed
to be followed on a quarterly basis for up to two years.
Questionnaires
were administered and CD4 cell counts and viral loads taken at each visit.
Those with eligible CD4 cell counts were referred to a local PEPFAR-funded treatment
centre approximately 500 metres from the study clinic where CD4 cell counts
were done independently of the study.
Two-thirds
of the HIV infected partners were female. Median CD4 cell count at enrolment
was 405 cells/mm3 (IQR: 280-586 cells/mm3). Females were
younger with a median age of 28 years compared to 36 years for males and had
been in the relationship for a shorter time than the men, median length of 4.8
years compared to 6 years.
During
follow-up 33% (146) had eligible CD4 cell counts to start ART, of which 81
(55%) were female. The median time to starting ART from CD4 eligibility was 8.9
months (95% CI: 6.0-10.0). By six months from CD4 eligibility 42% had started
ART and by one year 63.4% were on ART.
CD4
cell count at the time of eligibility was the strongest predictor for starting
ART. The lower the CD4 cell count the shorter the time to starting ART; 56.3%,
42.6% and 32.2% by six months for those with eligible CD4 cell counts of under
100, 100-200 and 200-250, respectively.
The
authors note such findings highlight potential future challenges as guidelines
recommend starting ART at higher CD4 cell counts. Those with lower CD4 cell
counts are sicker and more likely to want to start treatment, whereas those
with higher counts may not feel unwell, are worried about side effects and so
delay starting treatment.
Contrary
to other studies the authors did not find that men started ART more slowly than
women and suggested this was because of the nature of the study population who
willingly engaged in care by agreeing to participate.
The
authors undertook a secondary analysis looking at ART start and its association
with a woman becoming pregnant. They found that women on ART were less likely
to become pregnant compared to those not yet on ART (4.5 per 100 woman years
and 10.7 per 100 woman years, respectively).
Additionally
there was evidence to suggest that women starting ART chose not to become
pregnant. Women were 81% more likely to report using hormonal contraceptives
after starting ART than those not yet on ART (RR=1.81, 95% CI: 1.02-3.19).
These findings, they note, contradict previous findings of higher rates of
fertility of women on ART.
While
they suggest differences may be explained by differences in the study
populations and follow-up time, they stress the critical need in the management
of women with HIV for access to family planning resources as well as a better
understanding of the decision-making process among women and their reproductive
wishes and starting ART.
Strengths
of the study include a relatively large sample size and long period of follow-up.
Limitations
that preclude generalising these findings: this study is a research cohort
where both partners were aware of each other’s status so leading to faster
start of ART, especially among men. Regular and consistent counselling over a
two-year period probably resulted in a higher uptake so underestimating the
true extent of the problem in the general population.
The
authors conclude even where treatment is accessible and free, delays in
starting ART persist. “Factors of lower socioeconomic status may slow starting
ART and targeted approaches are needed to avoid such delays."